中国临床药学杂志

参考文献

[1]MUESER K T,MCGURK S R.Schizophrenia[J].Lancet,2004,363(9426):2063.

[2]KAHN R S,SOMMER I E,MURRAY R M,et al.Schizophrenia[J].Nat Rev Dis Primers,2015,1:15067.

[3]LEUCHT S,TARDY M,KOMOSSA K,et al.Antipsychotic drugs versus placebo for relapse prevention in schizophrenia:a systematic review and meta-analysis[J].Lancet,2012,379(9831):2063.

[4]HUHN M.NIKOLAKOPOULOU A,SCHNEIDER-THOMA J, et al.Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia:a systematic review and network meta-analysis[J].Lancet,2019,394(10202):939.

[5]GALDERISI S,MUCCI A,BUCHANAN R W,et al.Negative symptoms of schizophrenia:new developments and unanswered research questions [J].Lancet Psychiatry,2018,5(8):664.

[6] BOWIE C R,HARVEY P D.Cognitive deficits and functional outcome in schizophrenia[J].Neuropsychiatr Dis Treat,2006,2(4):53 1.

[7]BLAIR H A.Lumateperone:first approval[J].Drugs,2020,80(4):417.

[8]陈本川.治疗精神分裂症新药:对甲苯磺酸芦玛哌酮(lumateperone tosylate)[J].医药导报,2020,39(8):1170.

[9]张海枝,陈会慧,刘长鹰,等.新型多靶点5-羟色胺受体抑制剂ITI-007[J].现代药物与临床,2016,31(2):250.

[10] Medchem Express.Lumateperone tosylate SDS MedChemExpress[EB/OL].(2017-07-13)[2021-02-16].https://file.medchemexpress.cn/batch_PDF/HY-19733/Lumateperone-tosylateSDS-MedChemExpress.pdf.

[11]FDA.Caplyta(lumateperone)capsules,for oral use [EB/OL].(2019-12-20)[2021-02-16].https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/2 09500s0001bl.pdf.

[12]SNYDER G L,VANOVER K E,ZHU H W,et al.Functional profile of a novel modulator of serotonin,dopamine,and glutamate neurotransmission[J].Psychopharmacology(Berl),2015,232(3):605.

[13]DAVIS R E,VANOVER K E,ZHOU Y,et al.ITI-007 demonstrates brain occupancy at serotonin 5-HT_(2A)and dopamine D_2 receptors and serotonin transporters using positron emission tomography in healthy volunteers[J].Psychopharmacology(Berl),2015,232(15):2863.

[14]VANOVER K E,DAVIS R E,ZHOU Y,et al.Dopamine D2receptor occupancy of lumateperone(ITI-007):a positron emission tomography study in patients with schizophrenia[J].Neuropsychopharmacology,2019,44(3):598.

[15]NDA.209500 Multi-disciplinary Review and Evaluation Caplyta(lumateperone)[EB/OL].(2017-12-20)[2020-02-16].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/2095000rigls000MultidisciplineR.pdf.

[16]FDA.209500 Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS [EB/OL].(2018-03-17)[2021-06-27].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/2095000rig1s000AdminCorres.pdf.

[17]VYAS P, HWANG B J, BRASIC J R.An evaluation of lumateperone tosylate for the treatment of schizophrenia[J].Expert Opin Pharmacother,2020,2 1(2):139.

[18]DAVIS R E,HENDRICK J, ZHANG L,et al.Poster#S78 the novel pharmacology of ITI-007 is enhanced and extended by its metabolic back conversion from IC200131[J].Schizophr Res,2014,153:S116.

[19]CORRELL C U,DAVIS R E,WEINGART M,et al.Efficacy and safety of lumateperone for treatment of schizophrenia:a randomized clinical trial[J].JAMA Psychiatry,2020,77(4):349.

[20]LIEBERMAN J A,DAVIS R E,CORRELL C U,et al.ITI-007for the treatment of schizophrenia:a 4-week randomized,double-blind,controlled trial[J].Biol Psychiatry,2016,79(12):952.

[21]Intra-Cellular Therapies,Inc..A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment [EB/OL].(2017-11-14)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT02469155?term=NCT02469155&draw=2&rank=1.

[22]CORRELL C U, VANOVER K E, DURGAM S, et al.P.673 Results from a 12-month open-label safety study of lumateperone(ITI-007)in patients with stable symptoms of schizophrenia[J].Eur Neuropsychopharmacol,2019,29:54-55.

[23]New York State Psychiatric Institute.ITI-007(Lumateperone Tosylate)for Schizophrenia[EB/OL].(2021-02-05)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT03 8 17528?term=NCT03 817528&draw=2&rank=1.

[24]Intra-Cellular Therapies,Inc..Pharmacokinetics,Safety,and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia [EB/OL].(2021-01-14)[2021-09-07].Pharmacokinetics,Safety,and Tolerability of Lumateperone LongActing Injectable in Patients With Schizophrenia-Full Text ViewClinicalTrials.gov.

[25]VANOVER K,DMITRIENKO A,GLASS S,et al.Lumateperone(ITI-007)for the treatment of schizophrenia:placebo-controlled clinical trials and an open-label safety switching study[J].Schizophr Bull,2018,44(suppl_1):S341.

[26]Intra-Cellular Therapies,Inc..Receptor Occupancy of ITI-007Using Positron Emission Tomography(PET)in Patients With Stable Schizophrenia [EB/OL].(2017-03-10)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT02288845?term=NCT02288845&draw=2&rank=1.

[27]GOUSE B M,CHANG A L,SMITH E G.Effect size and blinding in lumateperone trial[J].JAMA Psychiatry,2020,77(6):650.

[28]CORRELL C U, LAKKIS H D,VANOVER K E.Effect size and blinding in lumateperone trial-reply[J].JAMA Psychiatry,2020,77(6):651.

[29]D'SOUZA I,DURGAM S,SATLIN A,et al.Lumateperone(ITI-007)in the Treatment of Bipolar Depression:Results from a Randomized Clinical Trial[J].CNS Spectr,2021,26(2):150.

[30]Intra-Cellular Therapies,Inc..Clinical Trial Evaluating ITI-007(Lumateperone)as a Monotherapy for the Treatment of Bipolar Depression [EB/OL].(2021-04-14)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT02600494?term=ITI-007-401&draw=2&rank=1.

[3 1]Intra-Cellular Therapies,Inc..Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression [EB/OL].(2021-04-13)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT0 2600507?term=ITI-007-402&draw=2&rank=1.

[32]Intra-Cellular Therapies,Inc..Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder [EB/OL].(2021-08-10)[2021-09-07].https://clinicaltrials.gov/ct2/show/NCT04285515?term=ITI-007-403&draw=2&rank=1.

[33]Intra-Cellular Therapies,Inc..Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial With ITI-007 in Patients with Sleep Maintenance Insomnia.[EB/OL].(2009-03-10)[2021-02-26].https://ir.intracellulartherapies.com/newsreleases/news-release-details/intra-cellular-therapies-reportspo sitive-final-results-phas e-ii.

[34]Intra-Cellular Therapies,Inc..Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia [EB/OL].(2017-11-17)[2021-09-07].Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia-Full Text View-ClinicalTrials.gov.

[35]KANE J M,VANOVER K E,DURGAM S,et al.185 the safety and tolerability of lumateperone 42 Mg for the treatment of schizophrenia:a pooled analysis of 3 randomized placebocontrolled trials[J].CNS Spectr,2020,25(2):3 16.

[36]KANE J M,VANOVER K E,DURGAM S,et al.P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia:a pooled analysis of phase 2 and 3 studies[J].Eur Neuropsychopharmacol,2019,29:S453.